SCHEMBL19944093

SCHEMBL19944093

Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(S)O[C@H]3[C@H](F)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO[PH](=O)O[C@H]2[C@@H]1F

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19944505 1.00 STING1 (0.73) STING1
SCHEMBL22080421 1.00 STING1 (0.73) STING1
SCHEMBL23798346 1.00 STING1 (0.73) STING1
SCHEMBL23798485 1.00 STING1 (0.73) STING1
SCHEMBL22930655 0.96 STING1 (0.74) STING1
SCHEMBL22930661 0.96 STING1 (0.74) STING1
SCHEMBL18822954 0.96 STING1 (0.74) STING1
SCHEMBL22080517 0.94 STING1 (0.71) STING1
SCHEMBL23476779 0.94 STING1 (0.70) STING1
SCHEMBL23477393 0.94 STING1 (0.76) STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040053-B2 Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling CHINOOK THERAPEUTICS, INC. (US) 2021-06-22 — — US disclosed
US-20200179431-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2020-06-11 — — US disclosed
US-10449211-B2 Compositions and methods for activating “stimulator of interferon gene”—dependent signalling Aduro Biotech, Inc. (US) 2019-10-22 — — US disclosed
US-20180064745-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2018-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200179431-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING STING1, IRF3, CGAS STING1 1/4885
US-11040053-B2 Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling STING1, IRF3, CGAS STING1 1/4885
US-10449211-B2 Compositions and methods for activating “stimulator of interferon gene”—dependent signalling STING1, IRF3, CGAS STING1 1/4885
US-20180064745-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING STING1, IRF3, CGAS STING1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback